Integrin-mediated traction force enhances paxillin molecular associations and adhesion dynamics that increase the invasiveness of tumor cells into a three-dimensional extracellular matrix.

Title
Integrin-mediated traction force enhances paxillin molecular associations and adhesion dynamics that increase the invasiveness of tumor cells into a three-dimensional extracellular matrix.

Permalink
https://escholarship.org/uc/item/18t2s57s

Journal
Molecular biology of the cell, 28(11)

ISSN
1939-4586

Authors
Mekhdjian, Armen H
Kai, FuiBoon
Rubashkin, Matthew G
et al

Publication Date
2017-06-01

DOI
10.1091/mbc.e16-09-0654

Peer reviewed
Integrin-mediated traction force enhances paxillin molecular associations and adhesion dynamics that increase the invasiveness of tumor cells into a three-dimensional extracellular matrix

Armen H. Mekhdjian,†,1, FuiBoon Ka,†, Matthew G. Rubashkin,†, Louis S. Prahlf, Lalaynne M. Przybyla, Alexandra L. McGregor, Emily S. Bell, J. Matthew Barnes, Christopher C. DuFort, Guanqing Ou, Alice C. Chang, Luke Cassereaud, Steven J. Tan, Michael W. Pickup, Jonathan N. Lakins, Xin Ye, Michael W. Davidson, Jan Lammerding, David J. Odde, Alexander R. Dunn, and Valerie M. Weaver

†Department of Chemical Engineering, Stanford University, Stanford, CA 94305; †Center for Bioengineering and Tissue Regeneration, Department of Surgery, and †Departments of Anatomy, Bioengineering and Therapeutic Sciences, and Radiation Oncology, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, and UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143; †Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455; †Nancy E. and Peter C. Meinig School of Biomedical Engineering and Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853; †Whitehead Institute for Biomedical Research, Cambridge, MA 02142; †National High Magnetic Field Laboratory and Department of Biological Science, Florida State University, Tallahassee, FL 32306

ABSTRACT Metastasis requires tumor cells to navigate through a stiff stroma and squeeze through confined microenvironments. Whether tumors exploit unique biophysical properties to metastasize remains unclear. Data show that invading mammary tumor cells, when cultured in a stiffened three-dimensional extracellular matrix that recapitulates the primary tumor stroma, adopt a basal-like phenotype. Metastatic tumor cells and basal-like tumor cells exert higher integrin-mediated traction forces at the bulk and molecular levels, consistent with a motor-clutch model in which motors and clutches are both increased. Basal-like non-malignant mammary epithelial cells also display an altered integrin adhesion molecular organization at the nanoscale and recruit a suite of paxillin-associated proteins implicated in invasion and metastasis. Phosphorylation of paxillin by Src family kinases, which regulates adhesion turnover, is similarly enhanced in the metastatic and basal-like tumor cells, fostered by a stiff matrix, and critical for tumor cell invasion in our assays. Bioinformatics reveals an unappreciated relationship between Src kinases, paxillin, and survival of breast cancer patients. Thus adoption of the basal-like adhesion phenotype may favor the recruitment of molecules that facilitate tumor metastasis to integrin-based adhesions. Analysis of the physical properties of tumor cells and integrin adhesion composition in biopsies may be predictive of patient outcome.

Monitoring Editor Alpha Yap University of Queensland

Received: Sep 12, 2016 Revised: Mar 24, 2017 Accepted: Mar 29, 2017

This article was published online ahead of print in MBoC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E16-09-0654) on April 5, 2017.

†These authors contributed equally.

The authors declare no conflicts of interest.

*Address correspondence to: Valerie M. Weaver (Valerie.Weaver@ucsf.edu), Alexander R. Dunn (alex.dunn@stanford.edu).

Abbreviations used: AFM, atomic force microscopy; 3B, Bayesian analysis of bleaching and blinking; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; FA, focal adhesion; FAK, focal adhesion kinase; FRET, Förster resonance energy transfer; ILK, integrin-linked kinase; MEC, mammary epithelial cell; MTS, molecular tension sensor; PA, polyacrylamide; PINCH, particularly interesting new cysteine-histidine–rich protein; SAIM, scanning angle interference microscopy; TFM, traction force microscopy; TGFβ, transforming growth factor β.

© 2017 Mekhdjian, Kai, Rubashkin, et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution—Noncommercial—Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).

“ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology.
INTRODUCTION

Metastasis is the main cause of death in patients with malignant tumors (Weigelt et al., 2005; Johnson et al., 2013; Lobbezoo et al., 2015). Tumor metastasis proceeds through a series of critical steps that include invasion of malignant cells across the basement membrane and their directed migration into the parenchyma, where they form invasive carcinomas (Rowe and Weiss, 2008; Egeblad et al., 2010). Thereafter, to metastasize, the malignant cells must migrate through the interstitial extracellular matrix (ECM) toward blood vessels and intravasate into the vasculature, where they can circulate as single cells, as cellular aggregates, or within fibrin-rich emboli (Masagué and Obenauf, 2016). Eventually, the disseminated “circulating” tumor cells either die or adhere to the capillaries of distal tissues, where they can extravasate. Once at the secondary site, the tumor cells must proliferate and recruit a new vasculature to form metastases (Nguyen et al., 2009; Telerman and Amson, 2009; Chaffer and Weinberg, 2011). Each of these steps favors tumor cells that migrate efficiently through a dense, collagen- and fibronectin-rich ECM, as well as cells that are able to retain their viability during intravasation and extravasation—processes that demand considerable cellular and nuclear squeezing and distortion (Friedl and Wolf, 2003; Egeblad et al., 2010; Roussos et al., 2011; Bravo-Cordero et al., 2012; Nguyen-Ngoc et al., 2012; Denais et al., 2016). Despite the clinical importance of metastasis and an appreciation of the physical hurdles that a tumor cell must overcome in order to disseminate, it remains unclear whether tumor cells exploit specific biophysical states or acquire unique mechanical properties to participate in the metastatic journey.

Cancer cell invasion and metastasis are influenced by the mechanical properties of the primary tumor and in particular the stiffness of the stromal ECM (Paszek et al., 2005; Levental et al., 2009; Pickup et al., 2013; Bae et al., 2014; Mouvou et al., 2014; Rubashkin et al., 2014a; Acerbi et al., 2015; Kai et al., 2016). A stiffened ECM fosters malignant transformation and metastasis of mammary tissue in vivo and stimulates the invasion of human and murine mammary epithelial cells (MECs) in vitro (Paszek et al., 2005; Levental et al., 2009; Schedin and Keely, 2011; Pickup et al., 2013; Rubashkin et al., 2014a). The invasive front of human breast tumors is also stiffer, and the level of stiffness correlates with human breast tumor aggression (Acerbi et al., 2015). These findings are consistent with the general observation that cells tune their cytoskeletal tension to the stiffness of their underlying ECM (Engler et al., 2004; Discher et al., 2005; Paszek et al., 2005; Yeung et al., 2005; Saha et al., 2008; Butcher et al., 2009; Allen et al., 2012; Cosgrove et al., 2014; Chaudhuri et al., 2015). Invading tumor cells engage the ECM through integrins, a class of heterodimeric, transmembrane proteins that link the cytoskeleton to the surrounding ECM. In response to a stiff ECM, integrin receptors assemble into focal adhesions (FAs), micrometer-sized assemblies consisting of hundreds of proteins that, in addition to their mechanical roles, mediate signaling through multiple pathways (Hoffman et al., 2011). Mechanically activated signaling via integrin-based adhesions not only enhances tumor cell growth and survival, but it also drives tumor cell invasion and migration (Jaalouk and Lammerding, 2009; DuFort et al., 2011; Batra et al., 2012; Carisey et al., 2013; Ross et al., 2013; Yao et al., 2014; Rubashkin et al., 2014b; Paluch et al., 2015). Consistently, treatments that inhibit FA formation or that ablate FA signaling reduce cancer progression and metastasis (White et al., 2004; Huveneers et al., 2007; Provenzano et al., 2008; Sulzmaier et al., 2014; Winograd-Katz et al., 2014). These observations support a picture in which a stiffened stroma, contractile cancer cell cytoskeleton, and integrin-dependent intracellular signaling combine to support cancer growth and metastasis. However, the colonization of distant metastasis sites requires passage through a series of narrow constrictions. This would seem to pose a contradiction because a stiffened tumor cell should have a distinct disadvantage when attempting to navigate confined microenvironments during the process of metastasis.

One plausible explanation that could link matrix mechanics, adhesion dynamics, and metastatic potential may reside in the observation that metastatic tumor cells often exhibit traits consistent with an epithelial-to-mesenchymal transition (EMT)—a developmental process that is often hijacked by cancer cells (Egeblad et al., 2010; Taube et al., 2010; Craene and Berx, 2013; Jung et al., 2015). An EMT allows formerly epithelial cells to access a mesenchymal form of cell migration that conceivably facilitates cancer cell invasion within dense ECMs, permitting their efficient dissemination to form distant metastatic colonies (Chaffer and Weinberg, 2011; Craene and Berx, 2013; Lamouille et al., 2014). Canonical EMT is characterized by expression of key transcriptional regulators, including Twist, Snail, and Slug, leading to a loss in cadherin-dependent cell–cell adhesion and apical-basal polarity and increased cell–ECM adhesion and matrix metalloproteinase (MMP) expression (Yilmaz and Christofori, 2009; Przybyla et al., 2016). Moreover, whereas an EMT-like transition can be triggered by exposure to chemokines such as transforming growth factor β (TGFβ), it is also promoted by a stiff ECM that is located at the invasive front of tumors (Acerbi et al., 2015; Wei et al., 2015; Przybyla et al., 2016).

Of importance, the idea that tumor cells require an EMT to metastasize and that this transformation is associated with reduced cortical tension has been questioned (Thoelking et al., 2010; Buckley et al., 2012; Schneider et al., 2013; Fischer et al., 2015; Zheng et al., 2015). In some circumstances, metastasis is favored by tumor aggregates (Friedl et al., 2012; Nguyen-Ngoc et al., 2012; Cheung et al., 2016). Furthermore, intravital imaging clearly illustrates that tumor cells can invade as cellular collectives (Gaggioli et al., 2007; Hidalgo-Carcedo et al., 2010; Manning et al., 2015), a finding that accords well with the observation that metastatic cells often retain E-cadherin expression (Cheung et al., 2013; Aceto et al., 2014). A plausible alternative explanation for the apparently disparate theories that argue for either single EMT or collective tumor metastasis is that tumor cells may engage in a “partial” or “transient” EMT to disseminate (Chaffer and Weinberg, 2011; Jolly et al., 2015, 2016). Consistent with this proposition, live-cell imaging of tumor aggregates with a high propensity to metastasize revealed that the leader “invading” cells exhibited a basal-epithelial phenotype (for convenience, “basal-like”), with features reminiscent of a partial EMT (Cheung et al., 2013).

In summary, although evidence indicates that matrix mechanical properties can exert strong effects on cancer metastasis, the molecular mechanisms are poorly understood. In particular, whether a stiff ECM could foster tumor metastasis by inducing a “basal-like” or pseudo-EMT phenotype via mechanical, integrin-mediated signaling has yet to be determined. Moreover, whether this “basal-like switch” endows tumor cells with biophysical properties that potentiate the metastasis of the EMT-like cells and, if so, how, are not known. To investigate these possibilities, we interrogated the relationship between integrin adhesion dynamics, composition, and forces and the cellular biophysical properties that favor tumor cell invasion within a confined, stiffened three-dimensional (3D) ECM.

RESULTS

ECM stiffness stimulates tumor cell invasion and induces a basal-like phenotype

We first asked whether a stiffened tumor ECM could promote the metastatic behavior of mammary tumors by inducing a basal-like,
invasive phenotype (Pickup et al., 2013). We examined the behavior of mouse tumor colonies (Borowsky et al., 2005) generated by growing mammary epithelial cell (MEC) PyMT tumor cells within a reconstituted basement membrane (rBM; 3–5 d) to form colonies, followed by their embedding within a 3D collagen/fibronectin bioreactor (72 h), where they were either maintained without modification or subjected to uniaxial stretch (10%; 72 h). The uniaxial stretch induces local strain stiffening of the collagen gel, increasing its stiffness fivefold (from 0.5 to 2.5 kPa) without altering bulk ECM concentration or pore size (Cassereau et al., 2015; Figure 1, a and b). Phase contrast images of colonies 72 h after their embedding and manipulation showed that the PyMT tumor colonies within the soft collagen/fibronectin gels exhibited little to no invasion. However, PyMT tumor colonies subjected to a stiffened ECM invaded significantly, although not to the same extent as those treated with TGFβ to induce an EMT (Figure 1, c, and quantified in d). On further investigation, confocal images revealed that the PyMT colonies within the soft (0.5 kPa) collagen/fibronectin hydrogels retained their epithelial phenotype, as indicated by β-catenin localization to cell–cell junctions, maintenance of cortical actin organization, and intense cytokeratin K8/18 expression (Figure 1, e and f, and Supplemental Figure S1). In contrast, the PyMT MECs invading into the stiffened ECM gels exhibited hallmarks of a basal-like phenotype. This basal-like phenotype included loss of junctional β-catenin, reorganization of actin into linearized bundles parallel to the axis of invasion, and acquisition of cytokeratin K14 at the leader cells in the stiff gels had abundant Snail transcripts that approximated the level uniformly expressed by all cells in PyMT colonies that had undergone a complete EMT (Figure 1g). These findings are consistent with the idea that a stiffened ECM could promote tumor metastasis by inducing a basal-like or partial EMT phenotype.

**Metastatic tumor cells and tumor cells with a basal-like phenotype exhibit enhanced invasion within confined spaces**

A prerequisite for tumor metastasis is the efficient migration of tumor cells through a dense and stiffened ECM, followed by their invasation into the vasculature and extravasation into the metastatic site. These behaviors would plausibly be favored by more-compliant cells, as predicted to be exhibited by cells with either a basal or a mesenchymal phenotype after EMT (Sahai, 2007;
Swaminathan et al., 2011; McGrail et al., 2015). To test this idea, we examined the migration of PyMT tumor MECs through constricted microchannels that mimic the confined, stiff microenvironment through which metastasizing tumor cells would likely navigate (Davidson et al., 2015; Denais et al., 2016; Figure 2). We compared cell behaviors after induction of EMT by treatment with TGFβ to that of Met1 MECs, a PyMT variant that was previously shown to exhibit a propensity to metastasize and yet retain epithelial-like characteristics (Borowsky et al., 2005; Qian et al., 2011). TGFβ-treated PyMT MECs migrated more efficiently than untreated MECs through the confined channels, as indicated by significantly shorter transit times through the constrictions (Figure 2, a and b) and higher percentages of cells migrating through constrictions with a cross-sectional area of <10 μm² (Figure 2, c and d). Of importance, Met1 tumor MECs migrated as efficiently as the TGFβ-treated PyMT tumor MECs, implying that complete EMT is not a prerequisite for efficient migration through a confined space.

Because cells with increased mechanical deformability pass more easily through confined spaces, we concluded that it was possible that increased migration of TGFβ-treated PyMT MECs and Met1 MECs was due to altered cytoskeletal mechanical deformability. To test this idea, we used atomic force microscopy (AFM) to measure the average cortical elasticity of multiple tumor cells plated on 2.7-kPa gels, using a 5-µm bead-ligated cantilever with multiple indentations across the cellular surface (Figure 3a). The resulting force–indentation curves were fit to a Hertz model to estimate an effective elastic modulus (Figure 3b). Consistent with the notion that tumor cells with a higher propensity to metastasize are more compliant (Swaminathan et al., 2011), our AFM measurements revealed that the Met1 MECs had a modest but significant reduction in effective stiffness compared with the PyMT MECs (Figure 3, c and e). Nevertheless, the compliance of the EMT-induced PyMT MECs was similar to that of the less invasive, untreated PyMT MECs (Figure 3, c and e).

Another component of cellular deformability that modulates cell migration through a confined microenvironment is nuclear stiffness (Davidson et al., 2014; Harada et al., 2014; Lautscham et al., 2015; Denais et al., 2016). Micropipette aspiration experiments indicated that there was a modest but statistically significant increase in nuclear deformability in the EMT-induced PyMT MECs (Figure 3, f and g). The findings are consistent with the argument that an EMT increases nuclear deformability and non cortical stiffness to facilitate cell migration through confined spaces and that this could potentiate tumor metastasis.

Tumor cells that migrate more efficiently within a confined space are more contractile

We next explored whether the enhanced invasive phenotype observed by the metastatic and EMT-induced MECs in the confined channels was associated with differences in cell–ECM interactions, as measured by the degree of cell spreading and/or traction force generation. We used traction force microscopy (TFM; Munevar et al., 2001; Paszek et al., 2005) and compared traction forces exerted by the Met1 and the untreated versus EMT-induced PyMT tumor MECs plated on fibronectin-conjugated polyacrylamide (PA) gels with a stiffness calibrated to mimic that measured at the invasive front of the malignant human and murine mammary tissue stroma (~2.7 kPa; Munevar et al., 2001; Paszek et al., 2005; Laklai et al., 2016). We observed that both the TGFβ-treated PyMT MECs and the Met1 MECs generated higher maximal and total cellular traction forces (Figure 4, a, and quantified in b) and higher spread area (unpublished data). We also measured higher total and maximal adhesion traction forces and enhanced cell spreading in premalignant human MCF10AT MECs induced to undergo EMT by treatment with TGFβ as compared with their nontreated controls (Figure 4, c, and quantified in d). As expected, TGFβ-treated MCF10ATs also spread progressively more on hydrogel surfaces functionalized with increasing concentrations of fibronectin (Supplemental Figure S2).
Cells that underwent EMT frequently increase $\alpha_5\beta_1$ integrin expression, and fibronectin-ligated $\alpha_5\beta_1$ integrin can significantly enhance cell spread area and cell–ECM traction force (Mierke et al., 2011; Lamouille et al., 2014). Consistently, immunoblot and fluorescence-activated cell sorting (FACS) revealed more total and cell surface $\alpha_5$ integrin expression in the TGFβ-treated MCF10A and PyMT MECs (unpublished data). To determine whether higher $\alpha_5$ integrin expression could account for the observed gain in cell spreading and traction force generation observed in the TGFβ-treated MECs, we engineered MCF10A MECs to ectopically express higher total $\alpha_5$ integrin. After confirming more than a two-fold increase in cell surface $\alpha_5$ integrin expression by FACS, we assayed for cell spread area and traction force compared with paired control and TGFβ-treated MCF10A MECs. Whereas the MCF10A MECs expressing higher levels of $\alpha_5$ integrin spread more and exerted higher traction force in response to a fibronectin gel, the magnitude of the increase was significantly lower than that after induction of EMT by TGFβ treatment (Supplemental Figure S3).

In summary, these findings suggest that in addition to an increase in nuclear deformability, there may also be an association between the ability of cells to exert higher cell–ECM traction forces and their ability to migrate more efficiently through a confined microenvironment. The data also argue that this phenotype cannot be solely explained by differences in integrin heterodimer expression.

Motor-clutch model of cellular traction predicts higher force and cell spread area for cells that have an enhanced ability to migrate within a confined space

We next used computational modeling to explore the interplay between cell adhesion and cell-generated traction forces exerted on compliant substrates. We first modified an existing computational motor-clutch model of cellular traction generation on compliant substrates (Chan and Odde, 2008). In this model, myosin motors slide an F-actin bundle and transmit forces to a compliant substrate through physical extension of molecular “clutch” molecules that

3342. (g) Compiled nuclear protrusion length ($\Delta L$) as a function of time, indicating some nuclear softening in response to TGFβ treatment. Mean ± SEM (n = 120 cells from three independent experiments). Scale bar, 20 µm.
transiently engage the actin filament (Figure 5a). The model revealed that efficient force transmission depends on the number and biophysical properties of the motors and clutches, clutch binding and force-dependent unbinding rates, and substrate mechanical properties (Figure 5b; Bangasser et al., 2013). Maximal force transmission occurs at an “optimum” substrate stiffness, whereas clutch unbinding increases on softer or stiffer substrates, leading to inefficient force transmission (Bangasser et al., 2013). Actin retrograde flow is biphasic and inversely correlated with traction force, and a leading-edge protrusion rate can be used as a proxy for spread area, defined by the difference between protrusion and retrograde flow (Chaudhuri et al., 2015).

Simulated cells with larger numbers of both myosin II motors and integrin-mediated adhesion clutches are better spread and generate larger tractions on surfaces with increasing stiffness but then go through a maximum so that at even higher stiffness, area and force are decreased (Figure 5, c and d). The prediction of increasing area and force is consistent with the larger adhesion sizes and increased traction generation observed for Met1 MECs and TGFβ-treated PyMT and MCF10AT MECs relative to untreated PyMT and MCF10AT cells (Paszek et al., 2005), at least below the optimal stiffness. Within the stiffness range of ~0.1–10 kPa, our results are consistent with nontransformed MECs employing a “weak clutch” regime. In this regime, an imbalance of contractile force and clutch number results in a failure to spread and low traction forces that modestly increase near disease-level stiffness. On addition of TGFβ and induction of an EMT phenotype, the simulated MECs express larger numbers of both motors and integrin-mediated adhesions and shift to a “balanced motor-clutch” regime in which the clutch strength matches that of the motors, resulting in slower actin flow, enhanced cell spreading, and higher traction forces (Figure 5, c and d).

As previously described (Chan and Odde, 2008; Bangasser et al., 2013), the motor-clutch model predicts a decrease in cell spread area and traction force at a substrate stiffness extending beyond an optimum stiffness (here ~10 kPa for TGFβ-treated MCF10As). By contrast, many cell types remain well spread and generate large traction forces even on stiff substrates (Ghibaudo et al., 2008; Elosegui-Artola et al., 2014, 2016). We developed a modified motor-clutch model that includes force-dependent recruitment of adhesion components in response to substrate stiffness, similar to recently proposed models (Elosegui-Artola et al., 2014, 2016). Briefly, we incorporated a clutch recruitment feedback rate (r_{clutch}), which is proportional to the number of clutches experiencing force above a threshold (F_{threshold}), as well as a maximum number of clutches available to be recruited (n_{clutch,max}; see the Supplemental Material for model description). By varying key parameters within the feedback response (in particular, k_{add}, we recapitulate varying degrees of reinforcement on stiff substrates, with higher reinforcement values (k_{add} = 0.1–1 s^{-1}), yielding a monotonic trend (Supplemental Figure S4). Hence our PA gel results alone did not provide enough information to distinguish between the two models—either TGFβ-treated cells have a higher optimum stiffness due to increased motor and clutch number, or our results are consistent with engaging adhesion reinforcement on stiff substrates.

**Cells with a basal-like phenotype exert higher integrin-dependent force**

To explore the model predictions further, we tested whether the increased overall cellular traction forces observed in Met1 and TGFβ-treated PyMT and MCF10A MECs translated into an increase in molecular forces at the level of individual adhesion complexes. To do so, we employed molecular tension sensors (MTSs), which report the forces exerted on integrin molecules in living cells (Morimitsu et al., 2013, 2015; Chang et al., 2016). Briefly, this technique incorporates an elastic protein spring flanked by two fluorophores that form a FRET pair (Figure 6a). The MTSs have an integrin-recognition domain containing the linear RGD tripeptide, which binds fibronectin-binding integrins. When cells adhere specifically via their integrins to an MTS-coated substrate, tension on individual sensors causes the elastic protein to stretch and the fluorophores to move

**FIGURE 4:** Cells with a basal phenotype exert higher traction forces. (a) PyMT and Met1 cells were seeded on 2.7-kPa PA gels conjugated with fibronectin and embedded with fluorescent beads for TFM. The displacement fields reflect the relative positions of beads before and after cell lysis. At a substrate stiffness comparable to that of tumor ECM (~2.7 kPa), Met1 cells are more spread and exert more traction forces on the substrate. Induction of EMT in PyMT cells by treatment with TGFβ recapitulates the increase in traction forces observed with Met1 cells, with total traction force even greater than for the Met1 cells. (b) Quantification of cell traction parameters. Metastatic cells have significantly increased total cellular and maximum traction forces. Mean ± SEM (*p < 0.05; >5 cells). (c) TFM of MCF10ATs. Cells that undergo TGFβ-induced EMT exert higher traction forces than untreated cells. (d) Quantification of cell traction parameters. TGFβ-treated MCF10ATs have significantly higher traction forces. Mean ± SEM (*p < 0.05; >5 cells).

Scale bar, 20 µm (a, c).

Molecular Biology of the Cell
with the TFM data (Figure 4). In addition, both the Met1 MECs and the TGFβ-treated PyMT tumor MECs exhibited a modest but statistically significant increase in the average force per MTS sensor (Figure 6, c, and quantified in d). This integrin-force phenotype appears to be conserved: MCF10AAs that had undergone a TGFβ-induced EMT also spread more, assembled larger adhesions, generated higher total tractions as measured using MTSs, and exhibited a modest but consistent increase in the force per MTS compared farther apart, yielding a decreased fluorescence resonance energy transfer (FRET) signal. An average force exerted on an ensemble of sensors within a given pixel is then calculated using a previously determined calibration curve (Grashoff et al., 2010) modified to incorporate the specific fluorophores used in these studies (Figure 6b).

Using this approach, we found that both the TGFβ-treated PyMT MECs and the metastatic Met1 MECs generated higher total forces at their integrins than did the untreated PyMT MECs, consistent with the TFM data (Figure 4). In addition, both the Met1 MECs and the TGFβ-treated PyMT tumor MECs exhibited a modest but statistically significant increase in the average force per MTS sensor (Figure 6, c, and quantified in d). This integrin-force phenotype appears to be conserved: MCF10As that had undergone a TGFβ-induced EMT also spread more, assembled larger adhesions, generated higher total tractions as measured using MTSs, and exhibited a modest but consistent increase in the force per MTS compared...

**FIGURE 5:** Motor-clutch model of cellular traction predicts higher force and spread area for cells with a basal phenotype. (a) Motor-clutch model of cell traction, including myosin contractility, actin assembly/treadmilling/disassembly, clutches (linear elastic springs) with constant $k_{on}$ and variable $k_{off}$ rates (dependent on clutch strain, $\chi_{clutch}$), and a linear elastic compliant substrate. (b) Parameter descriptions and values used in motor-clutch simulations. (c) Model predictions of traction force calculated from the results of the simulation. Increasing number of motors and clutches leads to an increase in traction force with substrate stiffness and shifts the peak traction to a higher stiffness. (d) Model predictions of cell adhesion area that is extrapolated from the length of assembled filaments, which in turn depends on the number of motors and clutches. (e) TFM of MCF10A cells with and without TGFβ treatment seeded on PA gels of varying stiffness. Cell spread area was quantified from bright-field images, average stress was calculated from the displacement fields, and total force was quantified by multiplying average traction stress by the spread area of the cell (>10 cells). The total force values represent the sum of individual pixel forces underneath the cell body as a whole (average stress times spread area). Scale bar, 20 µm.
mental Figure S5), consistent with cells adhering to surfaces that are stiffer than their optimal stiffness (Bangasser et al., 2013). In addition, whereas the increased force per bond is statistically significant, it is relatively modest compared with the increase in overall traction force (Figure 6, c–f), implying that the number of motors and clutches both increased. Therefore we conclude that the results are consistent with a model in which EMT transition induces an increase in both motors and clutches while also shifting from a “weak clutch” regime to “balanced motor-clutch” regime (as in Figure 5, c and d) but are inconsistent with a model that relies entirely on a force-feedback reinforcement mechanism (as in Supplemental Figure S4, c and d).

FIGURE 6: Cells with a basal phenotype exert higher integrin-dependent force. (a) Schematic of integrin MTSs. (b) FRET efficiency is converted into force using a calibration curve previously determined (Grashoff et al., 2010) and modified for the fluorescent dyes used here. (c) When seeded on a coverslip densely coated with MTSs, Met1 cells and TGFβ-treated PyMT cells spread more readily and generate higher integrin-mediated forces than untreated PyMT cells. (d) Quantification of the total force and average force per integrin MTS, which are both higher for Met1 than with PyMT cells. TGFβ treatment of PyMT cells resulted in an increase in cell spread area (unpublished data), total integrin-mediated force per cell, and average force per MTS, similar to the values measured for Met1 cells (***p < 0.001; >15 cells by the Wilcoxon rank sum test). Box-and-whisker plots display the median (red), 25th and 75th percentiles (bottom and top edges of the box, respectively), and the most extreme data points not considered outliers (edge of whiskers). (e) Integrin MTS measurements for MCF10A cells treated with TGFβ. (f) There is an increase in total force and average force for the TGFβ-treated MCF10As compared with the untreated ones (***p < 0.001; >15 cells by the Wilcoxon rank sum test). In d and f, the total force values represent the sum of individual pixel forces specifically within segmented adhesions. Scale bar, 10 µm (c, e).
In sum, these data indicate that tumor MECs with an elevated propensity to metastasize (here, Met1) exert higher traction forces than less metastatic but malignant MECs (here, PyMT), due primarily to an increase in adhesion size, but also to an increase in the average force per integrin. This phenotype is shared by MECs that have undergone a TGFβ-induced EMT and should therefore also be recapitulated in the basal-like tumor MECs encountering a stiffened ECM (Figure 1, e–g). Indeed, when considered with the behavior of MECs invading into 3D, stiffened, confined ECMs or within microchannels (Figures 1 and 2), these findings suggest that tumor MECs that assemble larger adhesions and exert higher integrin-generated forces may be able to migrate more efficiently in confined microenvironments.

**The integrin adhesions in cells with a basal-like phenotype are more stable and elongated**

To clarify the molecular origins of the increased force per integrin within adhesions, we examined the organization and stability of the adhesions in epithelial MCF10AT MECs and compared our findings to those measured in MECs that had been induced to undergo an EMT by TGFβ treatment. We conducted live-cell imaging of focal adhesion turnover in MCF10AT cells with and without TGFβ treatment. Top row: control, bottom row: TGFβ-treated. Scale bar, 10 µm (main image), 1 µm (inset). (b) Cumulative distributions of adhesion lifetimes. Inset, quantification of mean adhesion lifetime; mean ± SEM (***p < 0.001; >150 adhesions from five cells total). (c) Focal adhesion microstructure of MCF10AT seeded on MTSs overexpressing paxillin-eGFP and imaged with TIRF and 3B superresolution microscopy. Scale bar, 3 µm (main image), 1 µm (zoom). (d) Quantification of mean adhesion length of MCF10AT cells. TGFβ-treated cells have significantly longer adhesions; mean ± SEM (***p < 0.001; >100 adhesions from five cells). (e) Tensin-positive fibrillar adhesion formation in MCF10AT overexpressing paxillin-mEmerald and tensin-mCherry. Scale bar, 3 µm. (f) Quantification of the spatial colocalization between tensin and paxillin in adhesions. TGFβ-treated cells have significantly more paxillin-tensin colocalization (*p < 0.05; >10 cells). Pearson’s correlation was calculated based on pixels within the focal adhesion areas. (g) Paxillin-mEmerald (N-terminal) axial position in focal adhesions in MCF10As measured with SAIM. Paxillin position is plotted as the relative axial distance from the silicon wafer coated with fibronectin. Scale bar, 5 µm. (h) SAIM axial height measurements of adhesion proteins tagged with fluorescent proteins in MCF10As with and without TGFβ treatment. Paxillin is the only protein to significantly change axial position >10 nm, suggesting that the position of paxillin moves relative to that of the adhesion as a whole. (i) Quantification of paxillin-GFP axial position in MCF10As with and without TGFβ treatment. Paxillin in treated cells is located at a significantly higher axial nanoscale position (*p < 0.05; >10 cells). (j) Representative images of the axial position of paxillin-mEmerald (N-terminal) in focal adhesions in PyMT and Met1 cells. Scale bar, 5 µm.

In sum, these data indicate that tumor MECs with an elevated propensity to metastasize (here, Met1) exert higher traction forces than less metastatic but malignant MECs (here, PyMT), due primarily to an increase in adhesion size, but also to an increase in the average force per integrin. This phenotype is shared by MECs that have undergone a TGFβ-induced EMT and should therefore also be recapitulated in the basal-like tumor MECs encountering a stiffened ECM (Figure 1, e–g). Indeed, when considered with the behavior of MECs invading into 3D, stiffened, confined ECMs or within microchannels (Figures 1 and 2), these findings suggest that tumor MECs that assemble larger adhesions and exert higher integrin-generated forces may be able to migrate more efficiently in confined microenvironments.
observed in fibroblasts and other mesenchymal cells (Morimatsu et al., 2015). Alterations in adhesion stability and structure plausibly reflect differences in molecular composition (Zamir et al., 1999; Yoshigi et al., 2005; Wolfenson et al., 2013). To investigate this possibility, we assayed the colocalization of tensin, a marker for fibrillar adhesions, with paxillin in MCF10AT MECs with and without TGFβ treatment (Figure 7e). Pearson’s correlation coefficient between paxillin and tensin was significantly higher for the TGFβ-treated MCF10As, suggesting that the differences in integrin adhesion size and shape were mirrored by changes in molecular composition (Figure 7f). To further probe potential differences in molecular architecture, we performed scanning angle interference microscopy (SAIM; Paszek et al., 2012; DuFort and Paszek, 2014) to measure the axial position of known adhesion proteins (Figure 7, g–i). We found that focal adhesion kinase (FAK), talin, vinculin, and zyxin retained the same relative axial positions in both MCF10A and TGFβ-treated MCF10As (referred to the coverslip; Figure 7 h). Intriguingly, the position of paxillin relative to the silicon wafer substrate increased from an average of ∼50 nm in the epithelial MCF10As to ∼65 nm in the TGFβ-treated, EMT-induced MCF10As (Figure 7i). SAIM imaging revealed a similar qualitative shift in paxillin height between the epithelial PyMT tumor MECs and their TGFβ-treated EMT-induced counterparts (Figure 7j). Of importance, paxillin phosphorylation alone could not account for the shift in molecular height observed after EMT induction, as revealed by studies in which a nonphosphorylatable paxillin (mutated at tyrosine residues 31 and 118 to phenylalanine; paxillinY31/118F) localized at the same height as a wild-type paxillin in paxillin-null mouse fibroblasts transfected with equal quantities of transgene (Supplemental Figure S6). These findings suggest that MECs that recapitulate a basal-like phenotype or that underwent a mesenchymal transition not only exert more cellular–ECM integrin traction forces, but also assemble integrin adhesions that may be more stable and acquire a distinct cellular and subcellular organization. **Proteomics identifies a protein complex implicated in tumor cell invasion and metastasis recruited to integrin adhesions in cells with a basal-like phenotype** We next sought to determine whether the differences in integrin adhesion force, stability, and cellular and subcellular organization observed in the cells with a basal-like phenotype translated into distinct differences in molecular composition. Given the significant height changes we observed in paxillin in the EMT-induced MECs, we used a mass spectroscopic proteomics approach termed Bio-ID (Roux et al., 2012) to explore whether this was reflected by altered molecular interactions. We fused a promiscuous b Estradiol ligase protein (BirA*) to the N-terminus of paxillin-eGFP and expressed this construct in MCF10A MECs treated with vehicle or TGFβ to induce an EMT (Figure 8a; Dong et al., 2016). Analagous measurements used BirA* fused to eGFP as a control for nonspecific biotinylation. Focusing on the consensus list of integrin adhesion proteins (Horton et al., 2015; Figure 8b), we found that particularly interesting new cysteine-histidine-rich protein (PINCH; gene name LIMS1) was the most significantly enriched associated protein proximal to paxillin in the TGFβ-treated MCF10A MECs (highly abundant in TGFβ-treated cells and not present in untreated cells). Intensity correlation analysis of immunostained human MCF10A MECs showed that the amount of PINCH in paxillin-rich adhesions increased significantly in MCF10A MECs after TGFβ treatment (Supplemental Figure S7). Indeed, even in the epithelial MCF10A MECs that assembled sizeable integrin adhesions, PINCH was largely absent or diffusely colocalized. PINCH forms a complex with integrin-linked kinase (ILK) and α-parvin and interacts with paxillin at focal adhesions (Legate et al., 2006), and knockout of PINCH suppresses migration and vinculin localization to adhesions (Gonzalez-Nieves et al., 2013). Consistent with observations that ILK modulates breast tumor aggression and metastasis in vivo and has been linked to an EMT phenotype (White et al., 2001; Persad and Dedhar, 2003; Hannigan et al., 2005), we observed ILK enrichment at paxillin adhesions in MCF10A MECs that had been induced to undergo EMT by TGFβ treatment (Figure 8d). Immunostaining also revealed ILK localized to the paxillin adhesions in the PyMT tumor MECs after TGFβ treatment and in the PyMT tumor MECs interacting with a stiff ECM compared with those plated on a soft ECM (Figure 8, e and f). Of importance, immunoblot analysis showed that overall levels of total paxillin and phosphorylated paxillin, as well as of ILK, remained largely unchanged after TGFβ treatment (Supplemental Figure S8a). Thus the enhanced association of ILK proximal to paxillin in adhesions in TGFβ-treated cells was not the result of increased ILK expression. Further, abrogating myosin-related contractility reduced the association of ILK to paxillin-rich adhesions, indicating that the enhanced molecular interactions to paxillin were favored under conditions of elevated actomyosin-generated force (Supplemental Figure S8, b and c; Schiller et al., 2013). These findings imply that the more prominent, longer-lasting integrin adhesions fostering by the elevated traction force in the metastatic and basal-like MECs facilitated the recruitment of a suite of paxillin-associated proteins that fosters tumor cell invasion within a dense and stiffened ECM. **Phosphorylation of paxillin by Src family kinases is elevated in the mammary tumor cells with a basal-like phenotype and enhances invasion within a stiff 3D ECM** Tumor cell invasion requires integrin adhesion turnover stimulated by the phosphorylation of key adhesion plaque proteins, including paxillin (Tumbarello et al., 2005). Immunofluorescence analysis revealed that phosphorylation of paxillin (tyrosine 31) was elevated in the TGFβ-treated MCF10A MECs (Figure 9a). Paxillin tyrosine 31 and 118 phosphorylation was also enhanced in the PyMT MECs induced to undergo EMT by TGFβ treatment and in the invasive Met1 tumor MECs (Figure 9b and Supplemental Figure S9). We also detected strong phosphopaxillin staining at paxillin adhesions in basal-like leader PyMT tumor MECs invading into the 3D collagen/fibronectin gels in response to ECM stiffening (Figure 9c). Critically, preventing paxillin phosphorylation through ectopic expression of a nonphosphorylatable paxillin mutated at tyrosine residues 31 and 118 to phenylalanine (paxillinY31/118F) to hinder adhesion turnover (Webb et al., 2004; Pasapera et al., 2010; Plotnikov et al., 2012) inhibited Met1 tumor cell invasion into a 3D stiffened collagen gel (Figure 9, d, and quantified in e). Paxillin phosphorylation is mediated predominantly by Src family kinases (Schaller, 2001), and our Bio-ID assay revealed that GIT2, a Src substrate, was enriched proximal to paxillin in TGFβ-treated MCF10A MECs (enrichment factor, ~4; Yu et al., 2009, 2010; Bianchi-Smiraglia et al., 2013; Figure 8b). We therefore examined whether Src activity was critical for the elevated paxillin phosphorylation and enhanced invasive phenotype of the Met1 MECs in response to a stiffened 3D collagen/fibronectin in the bioreactor. Consistently, treatment of the metastatic Met1 and PyMT multicellular spheroids with the Abl/Src inhibitor dasatinib (20 nM) reduced paxillin phosphorylation and significantly decreased invasion of the tumor cell within the stiffened collagen/fibronectin hydrogel (Figure 9). The clinical relevance of these findings was investigated by analysis of the Cancer Genome Atlas (TCGA) data set and patient...
survival (Györffy et al., 2013). Gene expression data analysis revealed that patients with invasive breast cancer stratified into those with lymph node–positive cancers that had high levels of paxillin transcript also had a significantly worse chance of survival ($p < 0.001$; hazard ratio of 1.46 at 10 yr vs. patients with low paxillin levels; Figure 9g). Examination of the mortality hazard ratio for breast cancer patients with high gene expression of other integrin adhesion proteins also showed that patients with high FAK expression had a significantly higher risk of death ($p < 0.02$; hazard ratio, 1.34), whereas high expression of β1 integrin or talin did not as- sociate with increased patient mortality (Supplemental Figure S10). Intriguingly, Src regulates FAK activity, FAK regulates integrin adhesion turnover, and FAK critically regulates cancer progression and metastasis (Deramaudt et al., 2014; Sulzmaier et al., 2014). Evaluation of reverse-phase protein array data derived from 892 human breast cancer patients further indicated that patients with

FIGURE 8: Proteomics identifies unique proteins recruited to paxillin in the integrin adhesions during EMT. (a) BioID technique. A control BirA*-eGFP construct and a BirA*-paxillin-eGFP construct are stably expressed in MCF10A cells, which are then treated with TGFβ to induce EMT. BirA*-paxillin-GFP localizes to FAs and biotinylates proteins adjacent to paxillin when biotin is added to the medium. Biotinylated proteins are isolated and identified by mass spectrometry. (b) Normalized spectral counts for the consensus adhesome were clustered on the basis of an uncentered Pearson correlation using Cluster 3.0 and visualized using Java TreeView. From a subgroup of known paxillin interactors, we identify GIT2, LIMS1 (PINCH), and vinculin as enriched in TGFβ-treated cells. Black indicates no protein detected in the +TGFβ−TGFβ scale bar, and gray indicates no enrichment relative to the control. (c) Model for potential paxillin associations altered in response to TGFβ treatment. PINCH, GIT2, and vinculin localize adjacent to paxillin, and these associations are enriched in TGFβ-treated cells. (d–f) Immunofluorescence images of paxillin (green) and ILK (magenta). ILK is enriched in paxillin-rich adhesions in (d) MCF10A cells treated with TGFβ and (e) PyMT cells treated with TGFβ. Scale bar, 10 µm (main image), 5 µm (inset). (f) Immunofluorescence images of paxillin and ILK in PyMT cells on stiff (6 kPa) and soft (0.4 kPa) PA gels coated with fibronectin, showing that stiffness and TGFβ treatment modulate the recruitment of ILK to paxillin-rich plaques. Scale bar, 10 µm (main image), 2 µm (inset).
Enhanced paxillin phosphorylation permits invasion in cells with a basal phenotype. (a) Paxillin localization to the basal surface in MCF10A cells with and without TGFβ treatment visualized with immunofluorescence staining and TIRF imaging of paxillin and phosphorylated paxillin, pPax[31]. Scale bar, 10 µm (main image), 1 µm (inset). (b) Paxillin expression in PyMT, Met1, and PyMT + TGFβ visualized with immunofluorescence staining and confocal imaging of paxillin and phosphorylated paxillin pPax[31]. Scale bar, 10 µm (main image), 1 µm (inset). (c) Paxillin expression of PyMT cell spheroids visualized in soft and stiffened 3D collagen gel. Leader cells in stiffened gel have higher levels of phosphorylated paxillin indicated by pPax[31] immunostaining. Scale bar, 20 µm (main image), 10 µm (inset). (d) A 3D collagen invasion assay of multicellular spheroids composed of Met1 cells overexpressing either paxillinWT or paxillinY31/118F in 2.5 mg/ml 3D collagen gels for 72 h. Scale bar, 100 µm. (e) Quantification of invasion. PaxillinWT overexpression significantly increased invasion compared with control or paxillinY31/118F overexpression, as determined by cross-sectional area of spheroid and protrusions and single-cell invasion (∗p < 0.05; >20 spheroids). (f) A 3D collagen invasion assay of multicellular spheroids composed of metastatic Met1 cells treated with dimethyl sulfoxide or 20 nM dasatinib, a Src/Abl inhibitor, in 2.5 mg/ml 3D collagen gels for 72 h. Dasatinib addition significantly decreased cell invasion, as determined by cross-sectional area and single-cell invasion (∗p < 0.05; >15 spheroids). Scale bar, 100 µm. Dasatinib addition decreased levels of paxillin phosphorylation visualized by pPax[31] immunofluorescence. Scale bar, 5 µm. (g) Kaplan–Meier survival curve of invasive breast cancer patients expressing either high or low levels of paxillin. High paxillin levels are associated with a significantly worse chance of survival (p < 0.001; hazard ratio 1.46 at 10 yr). (h) Src phosphorylation levels via RPPA in TCGA breast cancer patients separated into control and paxillin–up-regulated groups. Paxillin up-regulation is correlated with a significant increase in Src phosphorylation at tyrosine 416 (∗p < 0.05; >4200 patients).

Elevated levels of paxillin also had significantly higher levels of phosphorylated Src-416, likely reflecting increased Src activity (Figure 9h). Thus the clinical data suggest that elevated total and Src family kinase-dependent phosphorylated paxillin may constitute tractable prognostic markers for decreased survival of patients with breast cancer. The cell biology studies imply that Src family kinase-dependent phosphorylation of paxillin may detect tumor cells with an intrinsic or tension-induced basal-like phenotype.
In this study, we sought to understand the key cellular biophysical properties that endow breast tumor cells with a propensity to metastasize and in particular the ability to invade and migrate through confined spaces. We present evidence of underlying similarities between metastatic breast tumor cells, EMT-induced breast tumor cells, and breast tumor cells interacting with a stiffened ECM that exhibit a basal-like phenotype. In each of these cases, we found that the breast tumor cells assembled large, elongated, “mesenchymal-like” focal adhesions that exerted markedly higher forces than those assembled in analogous cells lines that were predominantly epithelial and less metastatic in nature. Our findings revealed that these intrinsic or microenvironment-induced differences in adhesion size and force output reflected alterations in adhesion architecture, turnover, and molecular composition. Of note, in each of these conditions, the paxillin adhesions in the invasive basal-like tumor cells associated with the recruitment of a suite of adhesion plaque proteins, including PINCH and ILK—components of the PINCH/parvin/ILK complex previously implicated in tumor cell invasion and metastasis (Persad and Dedhar, 2003; Legate et al., 2006). In each of the invasive, basal-like cells, the paxillin that was recruited to focal adhesions was highly phosphorylated, a finding that is consistent with the notion that integrin adhesion turnover is essential for tumor cell invasion (Deramaudt et al., 2014). Consistently, when the invasive breast tumor cells were treated with a broad-spectrum Src family kinase inhibitor that is currently used in the clinic to treat cancer, paxillin phosphorylation was reduced at focal adhesions, and the invasiveness of the metastatic breast tumor cells into a 3D stiff ECM was markedly decreased. Accordingly, our findings suggest that metastasis would be favored by tumor cells that either adopt or temporarily borrow a conserved, “EMT-like” or “basal-like” integrin adhesion phenotype with higher integrin-mediated traction force generation (Figure 10).

FIGURE 10: Mechanistic model. (a) ECM stiffness and induction of EMT enhance metastatic behavior, evidenced by increased invasion in 3D collagen matrices, expression of basal epithelial markers and Snail transcription in leader cells, and a higher propensity to migrate through small constrictions. (b) Adoption of a mesenchymal phenotype results in biophysical properties similar to those of basal-like cells, including higher integrin-mediated traction forces and more stable, elongated focal adhesions. (c) Axially scaled model of adhesion architecture changes in basal-like cells (TGFβ treated), showing the average increase in paxillin height of 15 nm. (d) EMT promotes the association of the ILK-PINCH-parvin (IPP) complex, vinculin, and Git2 directly to or in the vicinity of paxillin. Paxillin phosphorylation, mediated through kinases such as Src, regulate adhesion turnover and cell invasion.

DISCUSSION

In this study, we sought to understand the key cellular biophysical properties that endow breast tumor cells with a propensity to metastasize and in particular the ability to invade and migrate through confined spaces. We present evidence of underlying similarities between metastatic breast tumor cells, EMT-induced breast tumor cells, and breast tumor cells interacting with a stiffened ECM that exhibit a basal-like phenotype. In each of these cases, we found that the breast tumor cells assembled large, elongated, “mesenchymal-like” focal adhesions that exerted markedly higher forces than those assembled in analogous cells lines that were predominantly epithelial and less metastatic in nature. Our findings revealed that these intrinsic or microenvironment-induced differences in adhesion size and force output reflected alterations in adhesion architecture, turnover, and molecular composition. Of note, in each of these conditions, the paxillin adhesions in the invasive basal-like tumor cells associated with the recruitment of a suite of adhesion plaque proteins, including PINCH and ILK—components of the PINCH/parvin/ILK complex previously implicated in tumor cell invasion and metastasis (Persad and Dedhar, 2003; Legate et al., 2006). In each of the invasive, basal-like cells, the paxillin that was recruited to focal adhesions was highly phosphorylated, a finding that is consistent with the notion that integrin adhesion turnover is essential for tumor cell invasion (Deramaudt et al., 2014). Consistently, when the invasive breast tumor cells were treated with a broad-spectrum Src family kinase inhibitor that is currently used in the clinic to treat cancer, paxillin phosphorylation was reduced at focal adhesions, and the invasiveness of the metastatic breast tumor cells into a 3D stiff ECM was markedly decreased. Accordingly, our findings suggest that metastasis would be favored by tumor cells that either adopt or temporarily borrow a conserved, “EMT-like” or “basal-like” integrin adhesion phenotype with higher integrin-mediated traction force generation (Figure 10).

EMT has been proposed as a central, and even required, process in cancer metastasis (Chaffer and Weinberg, 2011; Tsai et al., 2012). Cells in epithelial tissues are polarized, nonmigratory, and linked by mechanically robust intercellular adhesion complexes (Przybyla et al., 2016). An EMT offers a conceptually attractive mechanism by which carcinoma cells could reverse these defining characteristics in order to migrate through surrounding tissues and establish distant metastases. Furthermore, invading malignant cells often exhibit at least some of the molecular hallmarks of EMT—for example, the expression and engagement of transcription factors such as Twist or Snail, which are considered defining features of EMT in a developmental context (Yilmaz and Christofori, 2009; Przybyla et al., 2016). However, recent work has challenged the centrality of EMT to malignancy. In mouse models, distant metastases preferentially formed from multicellular aggregates rather than single cells. Further, metastasizing cells remained linked by robust cell–cell adhesions and maintained expression of E-cadherin, whose loss is classically considered a hallmark of EMT (Cheung et al., 2013, 2016). In addition, cells invading into a 3D ECM from murine mammary tumor colonies, as well as human tumor colonies isolated from women with aggressive breast tumors, did not undergo a canonical EMT; instead, the leader cells adopted key features of a “basal-like” response while maintaining their epithelial phenotype (Nguyen-Ngoc et al., 2012; Cheung and Ewald, 2014). More broadly, mesenchymal cells—for example, fibroblasts—are not intrinsically tumorigenic, and in humans are less likely to become cancerous than cells from epithelial tissues (Quail and Joyce, 2013). Our findings are consistent with these observations and imply that tumors cells may merely temporarily or permanently exploit basal-like features to facilitate their metastasis.

In the context of breast cancer, the perspective that a tumor need not undergo a complete EMT to metastasize has led to a revised model in which malignant epithelial cells adopt key features of basal-like/partial EMT cells and whose phenotypic characteristics may facilitate multicellular invasion into the surrounding tissue. Our data showed that an ECM with a stiffness matching that of the breast cancer stroma induced the leader PyMT epithelial cells within a tumor colony to adopt characteristics consistent with the “basal-like/partial EMT” phenotype, including cytokeratin 14 and Snail expression and partial disassembly of cell–cell adhesions, that was associated with their invasion into the surrounding matrix as loose cellular aggregates extending from the primary colony. The findings illustrate how the tissue microenvironment can promote the adoption of a presumably transient “basal-like” program that fosters tumor cell dissemination without compromising the overall epithelial
phenotype (Cheung et al., 2013; Pickup et al., 2013). Our studies thus provide a plausible explanation for the seemingly irreconcilable multicellular versus EMT phenotype as metastatic promoters. Critically, our observations suggest that malignant cells can either permanently or transiently borrow critical elements of a mesenchymal phenotype, notably the ability to exert large tractions on their surrounding ECM that would facilitate their dissemination through confined spaces. Our findings also predict that tumor cells should be able to adopt this metastatic adhesion phenotype without surrendering essential elements of their epithelial phenotype, such as cell-cell adhesion, which we and others showed can enhance survival in response to chemotherapy and during metastasis and would favor their ability to form macroscopic tumors (Weaver et al., 2002; Loesner et al., 2010; Longati et al., 2013).

Metastatic cells that penetrate through confined spaces experience extensive cell deformation (Doyle et al., 2013; Wolf et al., 2013). In some studies, biophysical measurements revealed that metastatic tumor cells have a lower effective stiffness than their primary tumor counterparts (Darling et al., 2007; Swaminathan et al., 2011). A decrease in cell stiffness, believed to be linked to induction of an EMT, presumably provides the metastatic cell with a means to migrate through confined spaces (Osborne et al., 2014; McGrail et al., 2015). In our hands, the metastatic Met1 and EMT-induced PyMT MECs exhibited an enhanced ability to pass through confined channels relative to the less metastatic parental PyMT MECs. However, AFM indentation revealed that this enhanced migratory ability did not consistently correlate with an increase in cortical deformability. However, we recognize that the AFM indentation measurements performed in the present studies report cell cortical stiffness, whereas the overall elasticity of the cytoskeleton may differ significantly. Another important proviso is that alterations in nuclear deformability, as we showed, also change after TGFβ treatment-induced EMT, and this elevated compliance may itself significantly contribute to the cells’ ability to navigate through constrictions. Nevertheless, our findings do suggest that an increase in cytoskeletal compliance is not an absolute prerequisite for cell migration through a confined microenvironment (Pathak and Kumar, 2012; Charras and Sahai, 2014; Lautscham et al., 2015). Instead, our studies suggest that an obvious likely contributor to the ability of cells to pass through constrictions is the ability of the disseminating cells to generate substantial tractions at their ECM adhesions. In short, our observations are consistent with the idea that cells that have a higher propensity to metastasize are more contractile, and yet their nucleus is more deformable. Thus cell contractility and stiffness are not synonymous, particularly in a diseased state in which cells adopt different phenotypes and/or behaviors than during normal physiological function.

More broadly, generation of integrin–ECM traction by cancer cells is linked to matrix stiffening and matrix remodeling (Paszek et al., 2005; Schedin and Keely, 2011; Jansen et al., 2013; Rubashkin et al., 2014a), both of which are believed to contribute to metastasis (Lu et al., 2012; Pickup et al., 2014). Consistently, prior studies correlated increased traction stresses with metastatic potential, albeit using a variety of cancer cell types with diverse origins that may or may not reflect a true acquisition of a metastatic phenotype (Kraning-Rush et al., 2012). Here we found that the Met1 MECs and EMT-induced PyMT MECs increased their traction forces relative to the parental PyMT MECs, findings that are consistent with results reported here and elsewhere showing that a stiff ECM increases cellular traction force and fosters tumor cell metastasis (Paszek et al., 2005; Kraning-Rush et al., 2012; Pickup et al., 2013). Of interest, an increase in cellular traction force is required for endoderm specification and is proposed to guide osteogenesis and myogenesis (Lee et al., 2015; Taylor-Weiner et al., 2015). Our data are thus consistent with the general idea that increased traction forces exhibited by prometastatic cancer cells may reflect a selective hijacking of one critical aspect of the EMT phenotype.

We present a simple physical model, modified from previous iterations (Chan and Odde, 2008; Bangasser et al., 2013; Elosegui-Artola et al., 2016), that could explain the cell-level changes in adhesion and contractility that facilitate metastasis. A principal prediction arising from this model is that both enhanced cell ECM adhesion (an increased number of “clutches”) and increased contractility (an increased number of “motors”) are required for the increase in cellular traction that accompanies the malignant phenotype. Our experimental measurements of cellular ECM traction and adhesion size, architecture, and dynamics are consistent with this general prediction. In particular, our MTS measurements indicated large increases in cellular traction forces in all of the breast tumor cell lines with a prometastatic or an EMT-like phenotype and revealed that the forces were likely transmitted through larger force-producing integrin adhesions. Intriguingly, our data revealed that the average force per integrin complex was modestly increased, suggesting that, in addition to an increase in clutch number, individual bond properties were also altered by addition of TGFβ. For example, the increased force per bond could be due to a modest increase in the characteristic bond force (∫Fbond or modest decrease in basal clutch unbinding rate (∫koff). Higher forces at the single-integrin level may plausibly reflect force-mediated “outside-in” signaling to drive clutch and motor addition (as in our biophysical model), which would then link to integrin-dependent intracellular signaling to drive actomyosin-dependent cytoskeletal tension. In the case of metastatic tumors, which exhibit increased integrin-linked forces and elevated “oncoprotein-dependent” actomyosin contractility, this relationship is predicted to reset the state of cellular tensional homeostasis to a higher level (Paszek and Weaver, 2004; Laklai et al., 2016).

Our data suggest that differences in adhesion properties reflect changes in adhesion molecular composition. We found that the large, force-producing adhesions assembled in the MECs that had undergone an EMT recruited more PINCH and ILK, which comprise part of the PINCH/Parvin/ILK complex, which has been strongly implicated in tumor cell invasion and metastasis (Persad and Dedhar, 2003; Legate et al., 2006). Our findings are also consistent with cell studies implicating ILK in an EMT and transgenic mouse work showing that ILK overexpression promotes breast tumor progression, whereas its knockdown reduces tumor aggression (White et al., 2001; Hannigan et al., 2005; Serrano et al., 2012; Pang et al., 2016). Thus adoption of the EMT-like adhesion phenotype by tumor cells may favor the recruitment of key signaling molecules that facilitate tumor cell invasion. Consistently, we found that paxillin displayed a pronounced shift in z height relative to the membrane in cells that had gone an EMT, suggestive of a differential role in epithelial versus mesenchymal cells.

Adhesion turnover is required for cell migration and for the metastatic dissemination of malignant cells (Friedl and Alexander, 2011). Consistent with this concept, despite the fact that the mammary tumor cells that had undergone an EMT assembled large, distinct focal adhesions and recruited a large repertoire of adhesion plaque proteins, they were also highly dynamic. The integrin adhesions formed by the metastatic breast tumor cells, breast tumor cells induced to undergo an EMT, and the basal-like PyMT tumor colonies interacting with a stiffened ECM also had elevated levels of phosphorylated paxillin, an observation echoing prior reports that paxillin phosphorylation is higher in metastatic cells and...
in cells treated with TGFβ (Tumbarello et al., 2005). Phosphorylation of paxillin by Src family kinases acts to induce both adhesion growth and disassembly and hence serves as a master regulator of adhesion stability (Turner, 2000; Webb et al., 2004; Zaidel-Bar et al., 2006; Wolfenson et al., 2011). We found that tumor cells interacting with a stiffened 3D ECM also exhibited higher levels of phosphorylated paxillin at their integrin adhesions, which may reflect an adaptation of the cells’ inherent sensing response to a soft substrate (Plotnikov et al., 2012). Regardless, we showed that blocking paxillin phosphorylation either by point mutagenesis or by adding a small-molecule inhibitor of a Src family kinase used in the clinic blocked the 3D invasion of Met1 MECs. Moreover, epidemiological data indicate that high paxillin expression correlates with decreased patient survival, and phospho-array data show that elevated tumor paxillin associates with high Src kinase levels and activity. Thus alterations in adhesion structure and dynamics may be directly linked to patient outcome, and assessment of integrin adhesion composition may constitute an untapped prognostic indicator.

**MATERIALS AND METHODS**

**Cell culture and reagents**

MECs, including nonmalignant MCF10A (American Type Culture Collection; verified by epithelial cellular morphology in two dimensions), ability to form hollow, polarized acini in 3D rBM gels, and expression of epithelial markers, including E-cadherin and cytokeratins 8 and 14) and premalignant Ha-Ras–transformed MCF10AT (Karnofsky Cancer Institute; verified by epithelial cell morphology in two dimensions) were cultured as described (Rubashkin et al., 2014a). Tumorigenic MEC lines PyMT Flox3 and metastatic Met1 (kind gift of the Moses laboratory, Vanderbilt University) were cultured as described before (Borowsky et al., 2005).

The 3D multicellular spheroids were generated in rBM (Matrigel; Corning) suspension cultures as described (Rubashkin et al., 2014a). MCF10A and Met1 MECs were flow sorted on a FACSAria II cell sorter (BD Biosciences) via primary and secondary antibody staining for top ~20% or bottom ~20% expression of α5 integrin, β1 integrin, or α5β3 integrin. The chemokine human TGFβ at 10 nM (PeproTech or Sigma-Aldrich) was used for 3 d to induce mesenchymal behavior. The small-molecule inhibitor dasatinib was used at 20 nM (Cayman Chemical).

**Expression constructs**

Transient plasmid constructs included Clontech vectors containing N- and C-terminus–tagged vinculin-mEmerald, paxillin-mCherry, paxillin-mEmerald, farnesyl-mEmerald, farnesyl-mCherry, FAK-mEmerald, Talin-mEmerald, Talin-mCherry, Zyxin-mEmerald, Tensin-mEmerald, and Tensin-mCherry. Expression constructs were provided by the Davidson Lab. Piggybac transposable plasmids containing eGFP-paxillin and eGFP-paxillin*23/118F were synthesized and cloned (Epoch Life Science, Sugar Land, TX) into Bsal-digested pHULK piggyBac Mammalian Expression Vector–CometGFP (DNA 2.0).

Stable cell lines inducibly expressing BirA*-paxillin derivatives were prepared using a custom-built PiggyBac transposable vector, pPB puro Tet. Briefly, pPB puro Tet includes the hepatameredized tetacycline (tet) operator minimal CMV promoter, which drives expression of a transgene with a S’ chimeric intron and polyadenylation signal derived from bovine growth hormone. pPB puro Tet also includes an expression cassette for puromycin selection in reverse orientation. BirA* (Roux et al., 2012) was modified with three tandem repeats of the myc 9E10 epitope at the N-terminus and a 22–amino acid, C-terminal glycine- and serine-rich flexible linker (N22).

The modified BirA* was then cloned in-frame with full-length paxillin-eGFP (Addgene plasmid 15233) at the N-terminus, such that the final construct had 3xmyc-BirA*-N22-paxillin-eGFP in order from N- to C-terminus. A fusion of mEmerald to the C-terminus of myc-tagged BirA* served as a control.

Transient transfection was performed using either Lipofectamine 2000 reagent or the Lonza Nucleofector Kit V, with program T024 for all epithelial cell lines and U024 for other cell lines. Recombinant lentivirus of the tet-promoter rtTA (neo) was prepared by transient transfection into HEK-293T cells, generating lentivirus titer used to transduce cells, as previously described (Rubashkin et al., 2014a). Target cells constitutively expressing the synthetic reverse Tet transcriptional transactivator rtTas-M2 were prepared by transduction with a G418 selectable lentiviral vector. These cells were transiently transfected with pPB puro Tet constructs and an expression construct for a hyperactive piggyBac transposase pCMV-HAhyPBase (generous gift of Allan Bradley, The Wellcome Trust Sanger Institute; Yusa et al., 2011).

Stable cell lines were selected in 200 ng/ml G418, 380 ng/ml hygromycin, or 1 μg/ml puromycin and sorted on a FACSAria II cell sorter (BD Biosciences) for fluorescent protein expression. Expression of inducible protein-encoding gene was induced with 200 ng/ml doxycycline in culture medium for 1 d before experimentation.

**Hydrogel and substrate preparation**

Collagen gels were fabricated by diluting 2.5 mg/ml acid-solubilized rat tail collagen (BD) in 1:1 DEMEM-F12 (Invitrogen), neutralizing to pH 7.4 with 1 M NaOH. For 3D collagen gels, a base layer of ~250-μm thickness was cast at 37°C for 30 min, followed by a second layer that included the cell suspension, which was also allowed to solidify for 30 min. Two-dimensional (2D) PA gels (height ~200 μm) were fabricated by varying the acrylamide and cross-linker concentration and assessing stiffness using either ATM or a shear rheometer (Johnson et al., 2007). Red fluorescent beads (100 nm; Invitrogen) were incorporated in the PA gels at 1:300 dilution relative to the manufacturer’s concentration and centrifuged at 2000 RCF to move the beads to the top surface of the gels for TFM. PA gels were functionalized with 10 μg/ml human fibronectin (Millipore) as described (Lakens et al., 2012).

N-type [100]-orientation silicon wafer with 1933-nm silicon oxide (1 cm x 1 cm; Addison Engineering) and borosilicate glass coverslips (~150 μm thick) were cleaned by successive sonication in acetone and 1 M KOH (20 min), followed by chemical activation with silane (0.5% (3-aminopropyl)trimethoxysilane) and glutaraldehyde (0.5% in water). The substrates were then ultraviolet- and ethanol-sterilized and incubated overnight (4°C) in extracellular matrix (human fibronectin, 10 μg/ml; Millipore). Before use, substrates were washed in phosphate-buffered saline (PBS; five times; pH 7.4), treated with sodium borohydride (20 mg/ml), and washed with PBS. SAIM calibration wafers were prepared by sonicating carboxylate-modified red fluorescent spheres (100 nm; Invitrogen), following by bead deposition (5 × 10^9 beads/ml) in NaCl (100 mM) PBS solution as described (Paszek et al., 2012).

**Immunofluorescence**

Cells were cultured on various substrates overnight and then fixed with 4% paraformaldehyde (PFA; 2D: 20 min, room temperature; 3D: overnight, 4°C) and stained as described (Levental et al., 2009). Primary antibodies against paxillin (5H11, Millipore; 610620, BD; P1093, Sigma-Aldrich; 32084, Abcam), phospho–paxillin-tyrosine 118 (44-722G, Life Technologies; 2541, Cell Signaling), phospho–paxillin-tyrosine 31 (44-720F, Life Technologies), vinculin (hVIN-1, 1481)
Sigma-Aldrich; 700062, Invitrogen; V284, Santa Cruz Biotechnology), phospho–FAK-tyrosine 397 (44-625G, Invitrogen), vimentin (D21H3, Cell Signaling), β-catenin (8480, Cell Signaling), K14 (PRB-115P, Covance), K8+18 (20R-CP004, Fitzgerald Industries), PINCH (EP1944, Abcam), ILK (611803, BD), and Alexa Fluor–phalloidin (Invitrogen) were used. Secondary antibodies used include Alexa Fluor goat anti-mouse, anti-rabbit, and anti-rat (488, 568, and 633 conjugates). For ILK immunofluorescence (IF), cells were fixed in 100% ice-cold methanol.

Microscopy and analysis
Unless otherwise noted, SAIM, TFM, confocal, and spheroid invasion assay imaging were performed on motorized total internal reflection fluorescence (TIRF) inverted microscopes (Ti-E Perfect Focus System; Nikon) controlled by Meta Morph (Molecular Devices) and Nikon Elements software and equipped with 488-, 561-, and 640-nm lasers, 350/50 epifluorescence, a CSU-X1 spinning-disk confocal unit (Yokogawa Electric Company), electronic shutters, motorized stage, a scientific complementary metal-oxide-semiconductor (sCMOS) camera (Zyla 5.5 megapixel, Andor; or Orca Flash, Hamamatsu), and an electron-multiplying charge-coupled device (EMCCD) camera (QuantEM 512; Photometrics). Temperature and CO2 were controlled by an environmental chamber and proportional integral derivative–controlled heater (In-Vivo Scientific). Samples were imaged with 100×/1.49 numerical aperture (NA) TIRF oil-immersion, 40×/1.2 NA long-working-distance water-immersion, 20×/0.75 NA air, and 10×/0.45 NA air objectives. For live-cell imaging, phenol red-free growth medium with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; pH 7.4) was used. For 3D imaging, confocal image slices were taken at 0.2- or 1.0-µm slices and the individual planes were maximum intensity z-projected for 2D visualization. Custom software packages for image analysis were written in Python, using ImageJ and the Eclipse Development Environment in Linux. Images were subject to a Gaussian blur of 1.0 pixel to smooth background noise. Intensity and colocalization measurements of single confocal planes were calculated on a pixel-by-pixel basis. Single-cell invasion, acini and cell protrusions, and cell adhesion length were quantified manually and verified qualitatively across three independent experiments. Acini cross-sectional area was quantified with the free-hand selection tool in ImageJ. Focal lifetimes were quantified manually and verified qualitatively across three independent experiments. SAIM was performed as described (Paszek et al., 2012; Rubashkin et al., 2014a), using data analysis and 3D visualization programs written in Matlab and Python using libraries distributed by Enthought.

Collagen invasion assays in 3D bioreactor
PyMT organoids were cultured in rBM (Corning) for 3–5 d. The organoids were isolated by solubilizing the gels using PBS-EDTA. The isolated organoids were subsequently embedded in 2.5 mg/ml collagen I solution supplemented with fibronectin (1 μg/ml) and rBM (1%). The collagen gels were stretched in a tension bioreactor with 0 or 10% strain for 72 h (Cassereau et al., 2015). Organoids were fixed with 1% PFA overnight for subsequent IF staining. Snail-YFP knock-in reporter tumor cells were kindly provided by Robert Weinberg (Ye et al., 2015). Tumor cells were cultured in rBM for 3–5 d and transferred to either untreated or ribose-stiffened collagen gels. After 48 h, organoids were fixed and stained for indicated proteins.

Microchannel migration assays
Migration experiments in microfluidic devices were carried out as described previously (Davidson et al., 2014, 2015; Denais et al., 2016). Briefly, the migration devices contain 5-µm-tall channels with constrictions ranging from 1 to 15 µm in width. Migration channels are flanked on either side by two unconfined regions with a height of 250 µm (Davidson et al., 2015). Molds of the migration devices were generated using two-layered SU-8 photolithography as described previously (Davidson et al., 2014). Replicas of the molds were made from a two-component Sylgard 184 polydimethylsiloxane (PDMS) kit (Dow Corning) using the (1:10) manufacturer’s recipe and cured for 2 h at 65°C. After curing, devices were cut to size, and holes were punched for cell-seeding ports and media reservoirs. A plasma cleaner (Harrick Plasma) was used to covalently bind microfluidic devices to glass coverslips that had been soaked in 0.2 M HCl overnight, rinsed with water and isopropanol, and dried. To improve adhesion after plasma cleaning, the completed devices were heated on a hot plate at 95°C for 5 min before sterilization with 70% ethanol. Devices were rinsed and treated with 20 µg/ml fibronectin (Millipore) overnight at 4°C. After incubation, the devices were rinsed with 1x PBS and cell culture medium. For the experiments, 30,000 cells/device were loaded into each device and allowed to attach overnight. Experiments were conducted with a 0–10% fetal bovine serum (FBS) gradient across the constrictions to stimulate directed migration, with cell medium supplemented with 25 mM HEPES. Devices were sealed with a glass coverslip to minimize evaporation and placed on a temperature-controlled stage (37°C) of an inverted Zeiss Observer Z1 microscope equipped with a CCD camera (Photometrics CoolSNAP KINO) and a motorized stage. Images for time-lapse sequences were acquired every 10 min for at least 12 h through a 20x air objective (0.8 NA) using ZEN software (Zeiss).

Images were analyzed using ZEN and ImageJ. Cell transit times through constrictions were measured for individual cells based on time-lapse sequences, with the starting point defined by the frame showing the first signs of nuclear deformation as a cell entered into a constriction, and the ending point defined by the frame at which the cell had migrated through the constriction and the nucleus was no longer "pinched." The fraction of cells that had passed through the first row of constrictions was determined using the final frame of each time-lapse sequence (i.e., 36 h after cell seeding). We quantified the number of cells that were located beyond the first constriction and the total number of cells that entered the 5-µm-tall channels. All experimental results are based on at least three independent experiments. Statistical analysis of transit times was determined using a Kruskal–Wallis test with Dunn’s multiple comparisons because the transit times did not follow a Gaussian distribution. Fisher’s exact test was used to compare the fraction of cells that had passed the first constriction between different conditions. The SE of the cell fraction was calculated according to the equation describing the SE for a binomial distribution:

$$SE = \sqrt{\frac{p(1-p)}{n}}$$

where $p$ is the fraction of cells that passed through the first row of constrictions and $n$ is the total number of cells. Statistical tests were performed in GraphPad Prism.

Atomic force microscopy
Cells were seeded on polyacrylamide gels with 2.7-kPa stiffness for 18 h. Hydrogels were then placed on the center of a standard microscopy slide and anchored using two-sided tape. Cells were kept hydrated in a droplet of HEPES-buffered medium (at room temperature) while force measurements were performed on an Asylum Research (Santa Barbara, CA) MFP-3D atomic force microscope.
All samples were measured in liquid in contact mode using Nova
can 2.5-µm-radius beaded silica glass tip (k = 0.06 N/m) cantile
cers, which were calibrated by the thermal tune method. Force
measurements were collected at multiple points across the surface
of the gels and cells at a maximum trigger force of 2.0 nN. The
resulting force data were converted into elastic modulus using the
Hertz Model program in IgorPro v6.22A. Measurements were also
repeated with pointed-tipped Asylum Research TR400PB silicon
nitride (k = 0.02 N/m) cantilevers, showing a similar trend. Surface
plots were generated using the surf2f function in Matlab. To deter
mine cell elasticity, height cutoffs were chosen based on the height
maps to assign pixel values associated with the cell versus the gel.

**Micropipette aspiration**

Micropipette aspiration through 3-µm-wide, 5-µm-high channels
was performed using microfluidic devices fabricated as described in
Denais et al. (2016). PDMS molds of the devices were filled with a
2% bovine serum albumin (BSA)/0.2% FBS solution. Cells were tryp
sinized and resuspended in the 2% BSA/0.2% FBS solution contain
Hoechst 33342 for nuclear visualization. The cell suspension was
perfused into the devices at constant pressure using a MCF5-EZ
pressure controller (Flui gent). Channels were cleared by manual
backflushing, and nuclear deformation of cells entering the chan
nels was observed at 5 s intervals using a 20×/0.4 NA phase contrast
objective and Hamamatsu ORCA Flash 4.0 V2 camera. Images were
analyzed using a custom-written MATLAB algorithm.

**Traction force microscopy**

Cells were seeded overnight on PA gels with 100-nm fluorescent
red beads. Images of cells and beads were taken at 20× before add
ning 0.01% SDS to lyse the cells from the surface. A second picture of
the beads was taken afterward that was later aligned via the ImageJ
(http://rsb.info.nih.gov/j/) registration plug-in StackReg. To assess
bead movement, a particle image velocimetry (PIV) program was
implemented in ImageJ as described previously (Tseng et al., 2012).
The iterative scheme included a first pass at 32/64 (i.e., interroga
tion and search window size in pixels), followed by a second pass at
16/32, all at a correlation threshold of 0.60. Cross-correlation PIV
was used for traction measurements on gels of different stiffness,
with three iterative schemes of 128, 64, and 32 as the interrogation
window sizes. For PIV postprocessing, a normalized mean test
was used for traction measurements on gels of different stiffness,
resulting in one-dimensional (1D) forces, whereas experimental measures of traction force result
in 2D stresses on a compliant gel. To draw comparisons between
simulation and experiment, we used a previously described ap
proach to derive a relationship between 1D forces and 2D stresses
on a continuous substrate (Ghibaudo et al., 2008), as was previously
described for stochastic simulations of cell traction (Elosegui-Artola
et al., 2014, 2016). Here, \( P_{\text{traction}} \) is traction stress, and \( F_{\text{traction}} \) is traction
force:

\[
P_{\text{traction}} = \frac{F_{\text{traction}}}{\pi r^2_{\text{adhesion}} (\approx 1 \mu m^2)} \rightarrow P_{\text{traction}} = F_{\text{traction}}
\]

A compliant substrate is modeled as an elastic spring with stiff
ness constant \( k_{\text{substrate}} \) and effective Young’s modulus (\( E_{\text{eff}} \)) given by

\[
E_{\text{eff}} = \frac{9 \times k_{\text{substrate}}}{4 \pi r^4_{\text{adhesion}}} \rightarrow E_{\text{eff}} \sim 1.3 \times k_{\text{substrate}}
\]

**Integrin force sensor measurements**

The MT5s were adapted from sensors described previously
(Morimatsu et al., 2015), using cysteine-maleimide chemistry to at
ch the donor Alexa 546 dye and the acceptor Alexa 647 dye (Life
Technologies). This modified MT5 presents an RGD peptide derived
from fibronectin TYVATGRGDSPAA. Fusion perimeters were
attached to PEGylated coverslips as previously described (Morimatsu
et al., 2015). Briefly, labeled MT5s (~100 nM) were added to the flow
cell and incubated for 30 min, followed by Pluronic F-127 (0.2% wt/
vol) for ~1 min to prevent nonspecific cell attachment. All of these
steps were preceded by a PBS wash to remove excess reagent from

---

**Volume 28 June 1, 2017 High traction forces enhance invasion | 1483**
Images were then converted to FRET efficiency, $E$, to an average force per sensor molecule at each pixel, using a previously measured calibration curve modified to incorporate the photophysical properties of the dyes used here (Morimatsu et al., 2015).

A detailed explanation of calculations of the average force per sensor and total force per cell was given previously (Morimatsu et al., 2015). Briefly, to measure the average force per sensor, we first segmented the images from the paxillin-eGFP signal or the FRET index signal. These images were normalized, boxcar averaged with a rotating reference frame, and then thresholded to create a binary mask. The binary mask was used for a watershed algorithm to isolate individual islands, which were then combined and indexed with custom-written MATLAB code with minimum adhesion size of 0.5 mm². The average force per sensor was calculated by converting the FRET efficiency values to force values of individual pixels within the segmented regions. The total force per cell was calculated using FRET images of the entire cell taken on a Hamamatsu scCMOS camera. The FRET values in the segmented pixels were then converted to force and summed over all of the adhesions in the entire cell.

### 3B superresolution analysis

The 3B algorithm uses a Bayesian analysis technique to determine the positions of fluorophores based on patterns of blinking and bleaching events (Cox et al., 2011). Data were recorded on an EMCCD camera (Andor iXon) for ~200–300 frames at 20 frames/s. The images were then processed with the 3B algorithm on virtual machines hosted on Amazon's EC2 cloud computing service (Hu et al., 2013). Each calculation ran on the compute-optimized c3. large servers for ~40 iterations. The positions and intensities of the fluorophores as determined by the 3B analysis were plotted on a coordinate system scaled by a factor of three, representing a three-fold increase in effective resolution.

### Proteomics experiment and analysis

The biotin ligase protocol was modified from the previously published method (Roux et al., 2012), with some modifications outlined here. Four 10-cm dishes (~20 million cells) of MCF10A MECs stably expressing BirA* constructs were cultured on tissue culture plastic and treated with TGFβ for 3 d. The cells were then incubated in medium supplemented with 50 µM biotin (B4639; Sigma-Aldrich) for 24 h before lysis collection. Cells were detached using trypsin-EDTA, washed three times with cold DPBS, and resuspended in 1.6 ml of ice-cold RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40) with protease inhibitor cocktail (539134; Calbiochem). The lysates were incubated on ice for 1 h, followed by three sonication repeats using 10-s bursts at 30% amplitude and 30-s rest (Sonics VCX130). Supernatant was collected after 30-min centrifugation at 16,000 × g at 4 °C and incubated with 500 µl of DPBS-prewashed streptavidin Dynabeads (65001; ThermoFisher) overnight at 4 °C on an end-over-end mixer.

Dynabeads were collected the next day and washed for 5 min at room temperature twice with 1 ml of buffer 1 (2% SDS in H2O), once with 1 ml of buffer 2 (0.1% sodium deoxycholate, 1% Triton X-100, 500 mM NaCl, 1 mM EDTA, 50 mM HEPS, pH 7.5), once with 1 ml of buffer 3 (250 mM LiCl, 0.5% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, 10 mM Tris, pH 8.1), and then three times with 1 ml of buffer 4 (50 mM NaCl, 50 mM Tris, pH 7.4). After the last wash, beads were resuspended in 35 ml of SDS sample buffer saturated with biotin (250 mM Tris, pH 6.8, 0.57 M β-mercaptoethanol, 8% SDS, 40% glycerol) and boiled at 95 °C for 10 min. Purified proteins were separated on SDS–PAGE gel (NP0321BOX; ThermoFisher), stained with Coomassie dye (24615; ThermoFisher), and excised for mass spectrometry analysis.

Gel fractions were submitted to the Proteomics Facility at the Fred Hutchinson Cancer Research Center for mass spectrometry analysis. Briefly, desalted peptide samples were analyzed by liquid chromatography–electrospray ionization tandem mass spectrometry with a Thermo Scientific Easy-nLC II nano HPLC system coupled to a hybrid Orbitrap Elite ETD mass spectrometer using an instrument configuration as described (Xi et al., 2003). In-line desalting was accomplished by using a reversed-phase trap column packed with Magic C18-AQ (5-µm 200-Å resin; Michrom Bioresources, Auburn, CA), followed by peptide separations on a reversed-phase column packed with Magic resin and then directly mounted on the electrospray ion source.

Data analysis was performed using Proteome Discoverer 1.4 (Thermo Scientific, San Jose, CA). The data were searched against a Uniprot human database that included common contaminants. Sequest HT was used for database searching, and Percolator was used for scoring. Data acquired from the Orbitrap Elite were processed to generate normalized spectral count values for each protein. Similar to previously published techniques, each protein’s spectral counts were divided by the total number of spectral counts for that sample and then divided by the protein’s molecular weight (Horton et al., 2015). The resulting value was multiplied by 10⁶ and log₁₀-transformed to yield a score for each protein. Protein groups that had the same gene names (e.g., different isoforms or fragments of a larger protein) were combined to decrease redundancies in the analysis. Proteins or arrays were hierarchically clustered on the basis of an uncentered Pearson correlation using Cluster 3.0 and visualized using Java TreeView, as described previously (Horton et al., 2015).

### Human bioinformatics studies

To analyze survival as a function of transcriptomic data in human breast cancer patients, we used an online tool (www.kmplot.com; Györffy et al., 2013). The Affymetrix ID for paxillin was 201087_at. Briefly, the KMplot tool employs gene expression data and relapse-free and overall survival information from the Gene Expression Omnibus, the European Genome-Phenome Archive, and The Cancer Genome Atlas (TCGA) from >4000 patients. To analyze the effect of specific genes in survival, patient samples were split into two groups by predefined metrics for calculating quantile expression. Affymetrix transcriptome data for a user-selected probe were analyzed in KM-plot by autoselecting the best cutoff of gene expression, computing the median of expression over the entire database, and analyzing all
patient subtypes as long as they were lymph-node positive in the 2014 TCGA data set. All suggested quality controls were implemented (Györffy et al., 2013).

Reverse-phase protein array (RPPA) data from TCGA patients were analyzed using an online tool (www.cbiportal.org; Gao et al., 2013). Patients were separated into those with paxillin gene amplification, mRNA up-regulation, or protein up-regulation; and those without significant changes in paxillin at the gene, mRNA, or protein level. These two patient groups were then compared for differences in activated and phosphorylated signaling proteins (including Src phosphorylation at tyrosine 416) via previously conducted RPPA arrays.

**Statistics**

Statistical analysis for two groups was performed with an unpaired, two-tailed Student’s t test or Wilcoxon rank sum test where appropriate. For multiple comparisons, an analysis of variance test and Holm–Bonferroni t test were performed. Calculations were implemented in MATLAB, Python, and Prism.

**ACKNOWLEDGMENTS**

We thank Micah Dembo and Qingzong Tseng for providing TFM software and assistance, Allan Bradley for the hyperactive piggyBac transposase, Harold Moses for the PyMT Flox3 lines, Zena Werb for the Met1 cell line, Lisa Jones and the Proteomics Facility at the Fred Hutchinson Cancer Research Center for assistance with the protein identification studies, and Eva Huang and Gabriela Lomell at Stanford University for assistance with the BioID assay and quantification. We thank members of the Weaver, Dunn, Odde, and Lammerding groups for helpful discussions and technical insights. The trainee work was supported by a Department of Defense National Defense Science and Engineering Graduate Fellowship to M.G.R., the National Science Foundation Graduate Research Fellowship Program to A.H.M., L.S.P., A.L.M., G.O., and A.C.C., a 3M Science Merit award, a National Institutes of Health Research Postdoctoral Fellowship to F.K. Fund- ing was also provided by National Institutes of Health Grants R01- HL082792 to J.L., R01-CA172986 and U54-CA210190 to D.J.O., R01-GM112998-01 to A.R.D., R01-CA192914, CA174929, and U01- CA202241-01 to V.M.W., and U54-CA210184-01 to V.M.W. and J.L. In addition, this work was supported by Department of Defense Breast Cancer Research Program Scholar Expansion Award BC122990 to V.M.W. and Breakthrough Award BC150580 to J.L. and National Science Foundation Grant CBET-1254846 to J.L. This work was performed in part at the Cornell NanoScale Facility, which is supported by National Science Foundation Grant ECCS-15420819.

**REFERENCES**

Acerbi I, Casseraue L, Dean I, Shi Q, Au A, Park C, Chen YY, Liphardt J, Hwang ES, Weaver VM (2015). Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) 7, 1120–1134.

Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, et al. (2014). Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110–1122.

Allen JL, Cooke ME, Alliston T (2012). ECM stiffness primes the TGFβ pathway to promote chondrocyte differentiation. Mol Biol Cell 23, 3731–3742.

Bae YH, Mu KL, Hsu BY, Liu SL, Cretu A, Razinia Z, Xu T, Puré E, Assoian RK (2014). A FAK-Cas-Rac-lamellipodin signaling module transduces extracellular matrix stiffness into mecanosensitive cell cycling. Sci Signal 7, ra57.

Bangasser BL, Rosenfeld SS, Odde DJ (2013). Determinants of maximal force transmission in a motor-clutch model of cell traction in a compliant microenvironment. Biophys J 105, 581–592.

Batra N, Burra S, Siller-Jackson AJ, Gu S, Xia X, Weber GF, De Simone D, Breslowwald LF, Lefer EM, Sprague E, et al. (2012). Mechanical stress-activated integrin α5β1 induces opening of connexin 43 hemichannels. Proc Natl Acad Sci USA 109, 3359–3364.

Bianchi-Smargia A, Kunnev D, Limoge M, Lee A, Beckerle MC, Bakin AV (2013). Integrin-β3 and zyxin mediate formation of ventral stress fibers in response to transforming growth factor β. Cell Cycle 12, 3377–3389.

Borowsky AD, Namba R, Young LJT, Hunter KW, Hodgson JG, Tepper CG, McGoldrick ET, Muller WJ, Cardiff RD, Gregg JP (2005). Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis 22, 47–59.

Bravo-Cordero JJ, Hodgson L, Condeelis J (2012). Directed cell invasion and migration during metastasis. Curr Opin Cell Biol 24, 277–283.

Buckley ST, Meina C, Davies AM, Ehrhardt C (2012). Cytoskeletal rearrangement in TGF-β1-induced alveolar epithelial-mesenchymal transition studied by atomic force microscopy and high-content analysis. Nanomed Nanotechnol Biol Med 8, 355–364.

Butcher DT, Alliston T, Weaver VM (2009). A tense situation: forcing tumour progression. Nat Rev Cancer 9, 108–122.

Carsey A, Tsang R, Greiner AM, Nijenhuis N, Heath N, Nazgiewicz A, Kemkemer R, Derby B, Spatz J, Ballestrem C (2013). Vinculin regulates the recruitment and remodeling of core focal adhesion proteins in a force-dependent manner. Curr Biol 23, 271–281.

Cassereau L, Miroshnikova YA, Ou G, Lakens J, Weaver VM (2015). A 3D tension bioreactor platform to study the interplay between ECM stiffness and tumor phenotype. J Biotechnol 193, 66–69.

Chaffer CL, Weinberg RA (2011). A perspective on cancer cell metastasis. Science 331, 1595–1564.

Chan CE, Odde DJ (2008). Traction dynamics of filopodia on compliant substrates. Science 322, 1687–1691.

Chang AC, Mekhdjian AH, Morimitsu M, Denisin AK, Pruitt BL, Dunn AR (2016). Single molecule force measurements in living cells reveal a minimally tensioned integrin state. ACS Nano 10, 10745–10752.

Chamras G, Sahai E (2014). Physical influences of the extracellular environment on cell migration. Nat Rev Mol Cell Biol 15, 813–824.

Chaudhuri O, Gu L, Dannell M, Klumpers D, Bencherif SA, Weaver JC, Huebsch N, Mooney DJ (2015). Substrate stress relaxation regulates cell spreading. Nat Commun 6, 6364.

Cheung KJ, Ewald AJ (2014). Illuminating breast cancer invasion: diverse roles for cell-cell interactions. Curr Opin Cell Biol 30, 99–111.

Cheung KJ, Gabrielson E, Werb Z, Ewald AJ (2013). Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 155, 1639–1651.

Cheung KJ, Padmanabhan V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, Gorin MA, Verdone JE, Pienta KJ, Bader JS, et al. (2016). Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci USA 113, 201508541.

Cosgrove BD, Gilbert PM, Porpiglia E, Mourkioti F, Lee SP, Corbel SY, Cheung KJ, Gabrielson E, Werb Z, Ewald AJ (2013). Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 155, 1639–1651.

Cheung KJ, Padmanabhan V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, Gorin MA, Verdone JE, Pienta KJ, Bader JS, et al. (2016). Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci USA 113, 201508541.

Cosgrove BD, Gilbert PM, Porpiglia E, Mourkioti F, Lee SP, Corbel SY, Llewellyn ME, Delp SL, Blau HM (2014). Rejuvenation of the muscle stem cell population restores strength to injured aged muscles. Nat Med 20, 255–264.

Cox S, Rosten E, Monypenny J, Jovanovic-Talisman T, Burnette DT, Lippincott-schwartz J, Jones GE, Heintzmann R (2011). Bayesian localization microscopy uncovers nanoscale podozome dynamics. Nat Methods 9, 195–200.

Crane B, Berz G (2013). Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13, 97–110.

Darling EM, Zauscher S, Block JA, Guiik F (2007). A thin-layer model for viscoelastic, stress-relaxation testing of cells using atomic force microscopy: do cell properties reflect metastatic potential. Biophys J 92, 1784–1791.

Davidson PM, Denais C, Bakhshi MC, Lammersing J (2014). Nuclear deformability constitutes a rate-limiting step during cell migration in 3-D environments. Cell Mol Bioeng 7, 293–306.

Davidson PM, Silz J, Isermann P, Denais C, Lammersing J (2015). Design of a microfluidic device to quantify dynamic intra-nuclear deformation during cell migration through confining environments. Integr Biol (Camb) 7, 1534–1546.
Hidalgo-Carcedo C, Hooper S, Chaudhry SI, Williamson P, Harrington K, Györffy B, Surowiak P, Budczies J, Lánczky A (2013). Online survival analysis.

Gonzalez-Nieves R, Desantis AI, Cutler ML (2013). Rsu1 contributes to.

Gillespie DT (1977). Exact stochastic simulation of coupled chemical reactions.

Ghibaudo M, Saez A, Segall JE (2012). Classifying collective cancer cell migration. Nat Cell Biol 14, 777–783.

Gifford KE, Kryukov GV, Mungall AJ, Sunyaev SR, Birney E, Dunham I (2013). Computational identification of cancer genes.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqui RF, Roychowdhury D, Aftimos P, Elia G, et al. (2005). Integrin expression in prostate cancer.

Gilchrist M, Datta S, Liu T, Dhanasekaran S, Scher HI, Maitra A, Chuaqi...
High traction forces enhance invasion

Massagué J, Obenauf AC (2016). Metastatic colonization by circulating tumour cells. Nature 529, 298–306.

McGrail DJ, Mezencev R, Kieu GMN, McDonald JF, Dawson MR (2015). SNAIL-induced epithelial-to-mesenchymal transition produces concerted biophysical changes from altered cytoskeletal gene expression. FASEB J 29, 1280–1289.

Mitchell CT, Freey B, Feller M, Hermann M, Fabry B (2011). Integrin α5β1 facilitates cancer cell invasion through enhanced contractile forces. J Cell Sci 124, 369–383.

Morimitsu M, Mekhdjian AH, Adhikari AS, Dunn AR (2013). Molecular tension sensors report forces generated by single integrin molecules in living cells. Nano Lett 13, 3985–3989.

Morimitsu M, Mekhdjian AH, Chang AC, Tan SJ, Dunn AR (2015). Visualizing the interior architecture of focal adhesions with high-resolution traction maps. Nano Lett 15, 2220–2228.

Mouw JK, Yu Y, Damiano L, Bainer RO, Lakins JN, Acerbi i, Ou G, Wijekoon AC, Leventral KR, Gilbert PM, et al. (2014). Tissue mechanics modulate mRNA-dependent PTEN expression to regulate malignant progression. Nat Med 20, 360–367.

Munevar S, Wang Y-L, Dembo M (2001). Traction force microscopy of migrating normal and H-ras transformed 3T3 fibroblasts. Biophys J 80, 1744–1757.

Nguyen DX, Bos PD, Massagué J (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9, 274–284.

Nguyen-Ngoc KV, Cheung KJ, Brenot A, Shamir ER, Gray RS, Hines WC, Yaswen P, Werb Z, Ewald AJ (2012). ECM microenvironment regulates collective migration and focal dissemination in normal and malignant mammary epithelial cells. Proc Natl Acad Sci USA 109, E2595–E2604.

Osborne LD, Li GZ, How T, O’Brien ET, Blobe GC, Superfine R, Mythreye K, Munevar S, Wang Y-L, Dembo M (2001). Traction force microscopy of malignant tumor cells. Proc Natl Acad Sci USA 98, 10334–10339.

Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Pasapera AM, Schneider IC, Rericha E, Schlaepfer DD, Waterman CM (2011). Integrin-α5β1 in the basement membrane: who, when and how? Trends Cell Biol 18, 560–574.

Rubashkin MG, Casserea LL, Bainer R, DuFort CC, Yu Y, Ou G, Paszek MJ, Davidson MWD, Chen YV, Weaver VM (2014a). Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phos- phatidylinositol (3,4,5)-triphosphate. Cancer Res 74, 4597–4611.

Rubashkin MG, Ou G, Weaver VM (2014b). Deconstructing signaling in three dimensions. Biochemistry 53, 2078–2090.

Saha K, Keung AJ, Irwin EF, Li Y, Little L, Schaffer D V, Healy KE (2008). Substrate modulus directs neural stem cell behavior. Biophys J 95, 4426–4438.

Sahai E (2007). Illuminating the metastatic process. Nat Rev Cancer 7, 537–749.

Schaller MD (2001). Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20, 6459–6472.

Schedin P, Keely PJ (2011). Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb Perspect Biol 3, 1–22.

Schiller HB, Hermann M-R, Polleux J, Vignaud T, Zanivan S, Friedel CC, Sun Z, Raducanu A, Gottschalk K-E, Thériy M, et al. (2013). β1- and αv-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments. Nat Cell Biol 15, 625–636.

Schneider D, Baronsky T, Pietuch A, Rother J, Oelkers M, Fichtner D, Wedlich D, Janshoff A (2013). Tension monitoring during epithelial-to-mesenchymal transition links the switch of phenotype to expression of moesin and cadherins in NMuMG cells. PLoS One 8, e80068.

Serrano I, McDonald PC, Lock FE, Dedhar S (2012). Role of the integrin-linked kinase (ILK)/Fcat complex in TGF-β-induced epithelial–mesenchymal transition (EMT). Oncogene 32, 50–60.

Sulmaier FF, Jean C, Schlaepfer DD (2014). FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 14, 598–610.

Swaminathan V, Myrthreye K, Tim O’Brien E, Berchuck A, Blobé GC, Superfine R (2011). Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res 71, 5075–5080.

Taubé JH, Herschkowitz JI, Pathak A, Morin PJ, Applebaum FS, Westra WH, Lu Y, Wang Y, Zhu J, Wang Y, Becker J, et al. (2012). Integrin signaling in the baseline membrane: an overview. Cancer Res 72, 5557–5567.

Telerman A, Amson R (2009). The molecular programme of tumour rever- sion: the steps beyond malignant transformation. Nat Rev Cancer 9, 206–216.

Thelning G, Reiss B, Wegener J, Oberleithner H, Ravenstaedt H, Riethmuller C (2010). Nanotopography follows force in TGF-β1-stimulated epithelial cells. EMBO Rep 11, 921–928.

Tsi JH, Donaher JL, Murphy DA, Chau S, Yang J (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725–736.

Tseng O, Duchemin-Pelletier E, Deshieres A, Ballard M, Guillon H, Filhol O, Théry M (2012). Spatial organization of the extracellular matrix regulates cell-cell junction positioning. Proc Natl Acad Sci USA 109, 15449–15454.

Taylor-Weiner H, Ravi N, Engler AJ (2015). Traction forces mediated by integrin signaling are necessary for definitive endoderm specification. J Cell Sci 128, 1961–1968.

Telerman A, Amson R (2009). The molecular programme of tumour rever- sion: the steps beyond malignant transformation. Nat Rev Cancer 9, 206–216.

Vanbramer DA, Brown MC, Hetey SE, Turner CE (2005). Regulation of paxillin focal adhesion synthesis: the steps beyond malignant transformation. Nat Rev Cancer 5, 1038–1044.

Weaver VM, Lelièvre SS, Lakins JN, Chrenek MA, Jones JCR, Granco F, Werb Z, Bissell MJ (2002). Beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to
apoptosis in normal and malignant mammary epithelium. Cancer Cell 2, 205–216.

Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF (2004). FAK–Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 6, 154–161.

Wei SC, Fattet L, Tsai JH, Guo Y, Pai VH, Majeski HE, Chen AC, Sah RL, Taylor SS, Engler AJ, et al. (2015). Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat Cell Biol 17, 678–688.

Weigelt B, Peterse JL, van’t Veer LJ (2005). Breast cancer metastasis: markers and models. Nat Rev Cancer 5, 591–602.

White DE, Cardiff RD, Dedhar S, Muller WJ (2001). Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 20, 7064–7072.

White DE, Kuroki NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ (2004). Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6, 159–170.

Winograd-Katz SE, Fassler R, Geiger B, Legate KR (2014). The integrin adhesome: from genes and proteins to human disease. Nat Rev Mol Cell Biol 15, 273–288.

Wolf K, te Lindert M, Krause M, Alexander S, te Riet J, Willis AL, Hoffman RM, Figdor CG, Weiss SJ, Friedl P (2013). Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol 201, 1069–1084.

Wolfenson H, Bershadsky A, Henis YI, Geiger B (2011). Actomyosin-generated tension controls the molecular kinetics of focal adhesions. J Cell Sci 124, 1425–1432.

Wolfenson H, Lavelin I, Geiger B (2013). Dynamic regulation of the structure and functions of integrin adhesions. Dev Cell 24, 447–458.

Yao M, Goult BT, Chen H, Cong P, Sheetz MP, Yan J (2014). Mechanical activation of vinculin binding to talin locks talin in an unfolded conformation. Sci Rep 4, 4610.